ok_老虎社区_美港股上老虎

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":166596593,"tweetId":"166596593","gmtCreate":1624016040312,"gmtModify":1634024094029,"author":{"id":3578521859783514,"idStr":"3578521859783514","authorId":3578521859783514,"authorIdStr":"3578521859783514","name":"cins","avatar":"https://static.tigerbbs.com/23b0d5b7b45a4d7e14278a9c9794e20c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>ok</p></body></html>","htmlText":"<html><head></head><body><p>ok</p></body></html>","text":"ok","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/166596593","repostId":1133025835,"repostType":4,"repost":{"id":"1133025835","pubTimestamp":1624015886,"share":"https://www.laohu8.com/m/news/1133025835?lang=&edition=full","pubTime":"2021-06-18 19:31","market":"us","language":"en","title":"Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy","url":"https://stock-news.laohu8.com/highlight/detail?id=1133025835","media":"cnbc","summary":"The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about","content":"<div>\n<p>The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Piper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPiper Sandler upgrades Biogen, says Alzheimer's drug demand will be strong despite controversy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-18 19:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.cnbc.com/2021/06/18/piper-sandler-upgrades-biogen-says-alzheimers-drug-demand-will-be-strong-despite-controversy.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1133025835","content_text":"The demand outlook for Biogen’s new Alzheimer’s drug appears strong despite lingering concerns about the new treatment, and that should push the company’s stock higher, according to Piper Sandler.\nThe Food and Drug Administration’s approval of Aduhelm has been controversial, with multiple members of an FDA advisory committeeresigning in protestover the decision. There are concerns about the effectiveness of the treatment.\nPiper Sandler analyst Christopher Raymond said in a note to clients on Friday that he shared some of those concerns but that Aduhelm would still be a winner for Biogen’s business. Raymond upgraded the stock to overweight from neutral.\n“Despite our misgivings regarding FDA’s handling of the Aduhelm approval, we find two new data points too positive to ignore, and thus believe the path of least resistance on this stock is decidedly higher,” the note said.\nThose positive data points include a survey that shows strong demand and expected uptake for the drug, despite concerns about its effectiveness, and an expectation that Medicare and Medicaid will not significantly limit the available patient base for reimbursement, Piper Sandler said.\n“Combining this with what we see as a low-probability but still completely free call option that Biogen wins on appeal with the Tecfidera IP case, we think the stock is likely to go higher in the near term,” the note said.\nThe firm hiked its price target to $450 from $384, representing upside of 17% from where the stock closed on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":32,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/166596593"}